Merck Serono to run research projects with BioMed X
News Apr 04, 2013
The new research lab will allow Merck Serono to run projects with interdisciplinary teams of young scientists, coached by a supervisor at Merck Serono and an experienced academic in an open-innovation lab facility.
Merck Serono said the researchers from leading academic institutions worldwide will be selected through assessment centres based on their ‘scientific expertise, creative energy, and passion for product-oriented pre-clinical research and development’.
Under the terms of the agreement signed by both companies, Merck Serono will fund and run its own research projects on new treatments for cancer in the biomedical research lab. No financial terms have been disclosed.
‘Our goal is to seed and boost early stage research projects by placing them into a vibrant environment, bringing in top young talent to work at the interface between industry and academia in one of the top European research hubs in Heidelberg,’ said Bernhard Kirschbaum, Head of Global Research and Early Development at Merck Serono. ‘We expect this concept can result in a constant flow of innovative projects and creative talent into Merck Serono.’
In addition to operating the innovation centre, BioMed X will be responsible for worldwide recruiting of young talents, providing education to teams and securing access to academic research infrastructure in Heidelberg.
‘I believe forming teams of top life science talents from around the world and providing experienced mentors from academia and industry is a critical step to success,’ said Christian Tidona, Founder and Managing Director of BioMed X.
BioMed X’s goal is to establish and run innovation centres in major innovation hubs worldwide.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Targeting a Leaky Protein that Causes ParalysisNews
A rare genetic disorder in which people are overcome suddenly with profound muscle weakness is caused by a hole in a membrane protein that allows sodium ions to leak across cell membranes. Compounds containing a chemical group called guanidinium can block the pore created by the mutation and stop the sodium leak without altering the voltage sensor’s ability to function.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018